Journal article
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Abstract
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.
METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The coprimary outcomes were the percent change in anti-factor Xa activity after andexanet treatment and the …
Authors
Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB
Journal
New England Journal of Medicine, Vol. 380, No. 14, pp. 1326–1335
Publisher
Massachusetts Medical Society
Publication Date
April 4, 2019
DOI
10.1056/nejmoa1814051
ISSN
0028-4793